Abstract

 CADTH recommends that Trodelvy should be reimbursed by public drug plans for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received 2 or more prior therapies, at least 1 of them for metastatic disease if certain conditions are met.
 Trodelvy should only be covered to treat patients with triple-negative breast cancer that has spread to other parts of the body or cannot be removed by surgery, and who have received 2 or more prior treatments, including at least 1 treatment for metastatic disease; and have good performance status.
 Trodelvy should only be reimbursed if it is prescribed by a clinician who is experienced in treating cancer. The price of Trodelvy must be lowered to be cost-effective and affordable.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
